君圣泰医药-B(02511)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02511 君圣泰医药-B

香港特别行政区成立纪念日休市 06-30 15:49:33

2.680

-0.110

-3.94%

最高2.880	最低2.670	成交量7.55万
今开2.880	昨收2.790	日振幅7.53%
总市值15.30亿	流通市值15.30亿	总股本5.71亿
成交额20.63万	换手率0.01%	流通股本5.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02511","market":"HK","secType":"STK","nameCN":"君圣泰医药-B","latestPrice":2.68,"timestamp":1782805773955,"preClose":2.79,"halted":0,"volume":75500,"delay":0,"changeRate":-0.039426523297490995,"floatShares":571000000,"shares":571000000,"eps":-0.5883027555318499,"marketStatus":"香港特别行政区成立纪念日休市","change":-0.11,"latestTime":"06-30 15:49:33","open":2.88,"high":2.88,"low":2.67,"amount":206315,"amplitude":0.075269,"askPrice":2.79,"askSize":10000,"bidPrice":2.68,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.5479290370149582,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782955800000},"marketStatusCode":7,"adr":0,"listingDate":1703174400000,"exchange":"SEHK","adjPreClose":2.79,"openAndCloseTimeList":[[1782783000000,1782792000000],[1782795600000,1782806400000]],"volumeRatio":0.06154573541642047,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02511/tweets","defaultTab":"tweets","newsList":[{"id":"2647328063","title":"格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓！","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647328063?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:08","pubTimestamp":1782709733,"startTime":"0","endTime":"0","summary":"本次评选共设有14个奖项","market":"hk","thumbnail":"https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5373783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02511","03690","000338","00780","02105","02279","300760","01952","00600","02729","00917","06963","09880","09678","01497","02643","02553","01384","02408","002352","01833","01024","09959","01951","02121","002594","000039","09878","02526","002779","06668","002714","001248","000951","02718","01519","02661","300364","002600","01021","06979","09992","02687","02590","03692","02170","02273","02555","01768","07688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129388527","title":"君圣泰医药-B(02511)授予董事股份购回授权 规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1129388527","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129388527?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:05","pubTimestamp":1780409152,"startTime":"0","endTime":"0","summary":"君圣泰医药-B于公告中披露，董事会已建议授权公司可在特定期限内回购不超过已发行股份总数10%的股份。公司于最后实际可行日期的已发行股本总数约为571,325,668股，此次获授权最多可回购57,132,566股。公告同时提到，公司将于2026年6月24日至6月29日暂停股份过户登记，股东如欲参加当日召开的股东周年大会并行使投票权，须于2026年6月23日16时30分前办理过户手续。董事会建议持股股东按照公告提示关注会议安排及授权事宜，以确保合理行使相关权益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"君圣泰医药-B(02511)授予董事股份购回授权 规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179825268","title":"君圣泰医药-B更新5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1179825268","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179825268?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:53","pubTimestamp":1780303986,"startTime":"0","endTime":"0","summary":"2026年6月1日，君圣泰医药发布截至2026年5月31日的证券变动月报表。公告显示，公司法定/注册股本维持在1,000,000,000股普通股，面值每股0.0001美元，法定/注册股本总额为100,000美元，较上月无变化。截至2026年5月31日，公司已发行股份总数为571,325,668股，与上月持平，当月无新增发行、购回或注销活动，亦无公司库存股份产生。公眾持股比例维持符合香港联交所相关要求。公司确认本月所有股份相关事项均已遵循香港联交所《上市规则》及其他适用法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634049003","title":"格隆汇个股放量排行榜 | 5月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2634049003","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634049003?lang=zh_cn&edition=full","pubTime":"2026-05-09 17:30","pubTimestamp":1778319004,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日福田股份(08196)、优博控股(08529)、大行科工(02543)、信利国际(00732)、绿茶集团(06831)、兴证国际(06058)、马可数字科技(01942)、富通科技(00465)、粤港湾控股(01396)、千百度(01028)、大酒店(00045)、希慎兴业(00014)、长和(00001)、普拉达(01913)、中国海外发展(00688)、港铁公司","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/09173057055514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00465","00066","00215","02511","00839","02418","06031","02718","00669","01401","00085","00001","01028","00005","00014","00550","02552","06978","08529","00732","00243","00819","01083","01358","01876","02020","00012","00290","00010","02543","00365","00118","06669","02632","00688","00117","00752","01396","01113","00045","01942","00412","00017","00434","01828","00279","00546","00069","00813","01140"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2632316931","title":"君圣泰医药-B(02511)：陈明宇获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2632316931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632316931?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:06","pubTimestamp":1777885601,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君圣泰医药-B(02511)发布公告，陈明宇先生(陈先生)已获委任为独立非执行董事、本公司审核委员会(审核委员会)主席及本公司薪酬委员会(薪酬委员会)成员，自2026年5月4日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136382844","title":"君圣泰医药-B更新4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1136382844","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136382844?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:40","pubTimestamp":1777884033,"startTime":"0","endTime":"0","summary":"君圣泰医药-B于2026年5月4日发布截至2026年4月30日的月报表。公司全称为“君圣泰医药”，股票代码02511。报告显示，公司4月期间注册股本与已发行股份未发生变化。公司普通股法定/注册股本依旧为1,000,000,000股，面值每股USD 0.0001，截至4月末法定/注册股本合计USD 100,000，与上月持平。公司当月未发生新增发行、购回或注销股份等变动，也无涉及股票期权、可换股票据及其他协议或安排之更新。截至2026年4月底，公司股本总数保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118633582","title":"君圣泰医药-B（02511）聚焦CKM创新疗法，2025年度亏损收窄至2.32亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118633582","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118633582?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:35","pubTimestamp":1777462558,"startTime":"0","endTime":"0","summary":"君圣泰医药-B于本年度在糖尿病与心肝代谢系统疾病创新药领域继续深耕，核心产品及管线研究稳步推进。财务数据显示，2025年度公司年内亏损由上年的3.82亿元人民币收窄至2.32亿元人民币。行政开支约为5,910.20万元人民币，比去年同期减少27.2%。展望未来，君圣泰医药-B将继续深化在CKM领域的药物创新与临床研究，特别聚焦HTD1801及其他在研小分子药物在糖尿病、肥胖症、慢性肾脏病及相关肝病等领域的潜在应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"君圣泰医药-B（02511）聚焦CKM创新疗法，2025年度亏损收窄至2.32亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630318900","title":"君圣泰医药-B(02511.HK)授出最高1500万港元贷款","url":"https://stock-news.laohu8.com/highlight/detail?id=2630318900","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630318900?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:47","pubTimestamp":1777301223,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨君圣泰医药-B(02511.HK)公告，于2026年4月27日，公司与借款人刘利平订立贷款协议，据此，公司同意向借款人提供最高融资额达1500万港元的贷款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260427/32180948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130388941","title":"君圣泰医药-B更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1130388941","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130388941?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:48","pubTimestamp":1775033312,"startTime":"0","endTime":"0","summary":"君圣泰医药-B（股票代码：02511）于2026年4月1日披露2026年3月31日止月份的股份变动月报表。报告显示，截至本月底，公司法定/注册股本维持1,000,000,000股、每股面值USD 0.0001，总额USD 100,000，与上月保持一致。\n报告期内，公司已发行股份数为571,325,668股，无新增发行、购回、注销或库藏股变化，期末股本总数与上月相同。公司确认目前公众持股量符合香港联交所相关规定，不涉及股份期权、权证或可换股票据等变动。\n公司同时在公告中声明，所有股份发行及相关事宜均遵守《上市规则》及相关法律规定。本次公告由执行董事兼行政总裁刘利平博士签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622084061","title":"君圣泰医药-B(02511)发布年度业绩，股东应占亏损2.45亿元 同比减少35.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622084061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622084061?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:20","pubTimestamp":1774606852,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君圣泰医药-B 发布截至2025年12月31日止年度业绩，该集团取得其他收入1900.7万元，同比减少72.04%;公司拥有人应占亏损2.45亿元，同比减少35.84%;每股亏损0.51元。公司的研发团队在CKM相关疾病方面拥有丰富的专业知识、深刻的理解及广泛的开发经验。公司的研发团队由一组于药物开发方面具有多年经验的世界级科学家领导。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619953391","title":"君圣泰医药-B(02511.HK)拟3月27日举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2619953391","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619953391?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:07","pubTimestamp":1773396423,"startTime":"0","endTime":"0","summary":"格隆汇3月13日丨君圣泰医药-B(02511.HK)公告，董事会会议将于2026年3月27日(星期五)举行，藉以(其中包括)审议及批准公司及其附属公司截至2025年12月31日止年度经审核全年业绩及其发布，以及处理其他事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260313/32066952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618935382","title":"君圣泰医药-B(02511)：HTD1801的新药上市申请获中国国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2618935382","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618935382?lang=zh_cn&edition=full","pubTime":"2026-03-10 17:22","pubTimestamp":1773134579,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君圣泰医药-B(02511)发布公告，中国国家药品监督管理局(NMPA)已受理 HTD1801用于治疗2型糖尿病(T2DM)的新药上市申请(NDA)。这是君圣泰医药提交的首个新药上市申请，也是公司迈向产品商业化的重要里程碑。HTD1801已完成3项针对T2DM适应症的多中心、随机、双盲、对照的III期临床研究，均达主要终点和多项次要终点，在血糖、血脂、炎症、肾功能等多个心肾代谢关键维度呈现出一致的改善趋势，充分展现了其一药多效、综合获益的临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"君圣泰医药-B(02511)：HTD1801的新药上市申请获中国国家药品监督管理局受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618987412","title":"君圣泰医药大涨近20%创年内新高 暂四日连升累涨超66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618987412","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618987412?lang=zh_cn&edition=full","pubTime":"2026-03-10 15:45","pubTimestamp":1773128759,"startTime":"0","endTime":"0","summary":"3月10日，君圣泰医药-B今日高开高走，一度大涨19.25%至3.16港元，股价创年内新高。该股自上周四以来已连续4个交易日上涨，累涨超66%，大幅跑赢大盘及行业表现。消息面上，君圣泰医药今年2月上旬举行投资者会议，系统阐述了其以“一药多效”策略引领心肾代谢系统疾病综合治疗新时代的战略布局，并解读了多项关键临床进展。","market":"sh","thumbnail":"http://imgcloud.jrjimg.cn/2026/03/cms_20260310154559501.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/03/cms_20260310154559501.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/03/10154556248420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617483637","title":"君圣泰医药-B03月06日获主力加仓433.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617483637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617483637?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:15","pubTimestamp":1772784918,"startTime":"0","endTime":"0","summary":"03月06日, 君圣泰医药-B股价涨11.63%，报收2.40元，成交金额836.6万元，换手率0.59%，振幅23.72%，量比1.59。君圣泰医药-B今日主力资金净流入433.5万元，连续3日净流入，上一交易日主力净流入33.7万元。该股近5个交易日上涨3.90%，主力资金累计净流入1673.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1629.7万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161602a6aa29b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161602a6aa29b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617066845","title":"创新药板块强势 三生制药(01530)涨9.83% 机构指业绩兑现有望催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2617066845","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617066845?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:41","pubTimestamp":1772764875,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块强势，三生制药 涨9.83%，基石药业-B涨6.84%，荣昌生物涨6.31%，映恩生物-B涨5.98%，四环医药涨5.76%，恒瑞医药涨5.77%，君圣泰医药-B涨5.58%，康诺亚-B涨5.31%，复宏汉霖涨5.02%。交银国际表示，本周各公司业绩预告陆续发布，该机构建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976042","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","01530","HK0000306701.USD","BK1583","09995","02696","HK0000252152.HKD","LU2328871848.SGD","BK1593","HK0000306685.HKD","HK0000320264.USD","LU1969619763.USD","BK1161","02616","02162","09606","BK1191","00460","LU0359201612.USD","LU0359202008.SGD","BK1515","BK1600","01276","LU0359201885.HKD","06978","02511","HK0000500386.USD","BK1574","BK1587","159992","LU2543165471.USD","HK0000165453.HKD","HK0000252160.HKD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617595890","title":"君圣泰医药-B盘中异动 大幅下挫7.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617595890","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617595890?lang=zh_cn&edition=full","pubTime":"2026-03-04 09:55","pubTimestamp":1772589333,"startTime":"0","endTime":"0","summary":"2026年03月04日早盘09时55分，君圣泰医药-B股票出现异动，股价急速下挫7.22%。君圣泰医药-B股票所在的药品行业中，整体跌幅为0.36%。其相关个股中，德琪医药-B、开拓药业-B、凯莱英涨幅较大，振幅较大的相关个股有德琪医药-B、凯莱英、宝济药业-B，振幅分别为9.72%、8.12%、6.67%。君圣泰医药-B公司简介：君圣泰医药是一家生物制药公司,专注于就代谢及消化系统疾病的治疗发现、开发及商业化多功能及多标靶疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304095534a448f14d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304095534a448f14d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139747588","title":"君圣泰医药（02511）2月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1139747588","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139747588?lang=zh_cn&edition=full","pubTime":"2026-03-02 18:20","pubTimestamp":1772446840,"startTime":"0","endTime":"0","summary":"君圣泰医药3月2日公布截至2026年2月28日的股份变动月报表。本月公司注册股本与已发行股份规模保持稳定，未发生新增发行、购回或注销股份等活动。截至2026年2月28日，君圣泰医药的已发行普通股总数为571,325,668股，库藏股数为0股，合计已发行股份总数保持571,325,668股不变。本次公告由执行董事兼行政总裁刘利平博士签署。根据公告，截至2月底，公司总体股本规模未有新增或减少，未见重大变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616804974","title":"君圣泰医药-B盘中异动 早盘大幅下跌12.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616804974?lang=zh_cn&edition=full","pubTime":"2026-03-02 09:35","pubTimestamp":1772415345,"startTime":"0","endTime":"0","summary":"2026年03月02日早盘09时35分，君圣泰医药-B股票出现波动，股价大幅下挫12.99%。君圣泰医药-B股票所在的药品行业中，整体跌幅为0.63%。其相关个股中，海西新药、劲方医药-B、海王英特龙涨幅较大，振幅较大的相关个股有宝济药业-B、君圣泰医药-B、劲方医药-B，振幅分别为10.26%、8.66%、6.42%。君圣泰医药-B公司简介：君圣泰医药是一家生物制药公司,专注于就代谢及消化系统疾病的治疗发现、开发及商业化多功能及多标靶疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030209354597a78f05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030209354597a78f05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614015633","title":"君圣泰医药-B02月26日主力净流出27.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2614015633","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614015633?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:15","pubTimestamp":1772093731,"startTime":"0","endTime":"0","summary":"02月26日, 君圣泰医药-B股价跌4.15%，报收2.31元，成交金额186.7万元，换手率0.14%，振幅7.05%，量比2.08。君圣泰医药-B今日主力资金净流出27.5万元，上一交易日主力净流出0万元。该股近5个交易日下跌8.70%，主力资金累计净流出68.3万元；近20日主力资金累计净流出72.4万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226161715a7218675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226161715a7218675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611318186","title":"每日卖空追踪 | 君圣泰医药-B 02月12日卖空量成交2.8万股，卖空比例为13.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611318186","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611318186?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:30","pubTimestamp":1770885031,"startTime":"0","endTime":"0","summary":"君圣泰医药-B北京时间02月12日，跌1.9%，卖空量成交2.8万股，较上一交易日增加1766.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212163438a6f28cdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212163438a6f28cdd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hightidetx.com","stockEarnings":[{"period":"1week","weight":-0.053},{"period":"1month","weight":-0.1213},{"period":"3month","weight":-0.1383},{"period":"6month","weight":-0.0915},{"period":"1year","weight":0.0113},{"period":"ytd","weight":-0.0915}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"君圣泰医药是一家生物制药公司，专注于就代谢及消化系统疾病的治疗发现、开发及商业化多功能及多靶点疗法。该公司自主开发了多个候选产品的产品管线，涵盖代谢和消化疾病的多种适应症，其中部分产品处于临床阶段。该公司的核心产品HTD1801（小檗碱熊去氧胆酸盐）是一种新分子实体，作为肠肝抗炎代谢调节剂，靶向调节对人体代谢过程中至关重要的多个通路，包括与代谢及消化系统疾病相关的通路。该公司在美国、中国大陆、香港和澳大利亚开展业务。","exchange":"SEHK","name":"君圣泰医药-B","nameEN":"HIGHTIDE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君圣泰医药-B(02511)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君圣泰医药-B(02511)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君圣泰医药-B,02511,君圣泰医药-B股票,君圣泰医药-B股票老虎,君圣泰医药-B股票老虎国际,君圣泰医药-B行情,君圣泰医药-B股票行情,君圣泰医药-B股价,君圣泰医药-B股市,君圣泰医药-B股票价格,君圣泰医药-B股票交易,君圣泰医药-B股票购买,君圣泰医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君圣泰医药-B(02511)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君圣泰医药-B(02511)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}